A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

This study tests a new drug called PTX-100 for people with cutaneous T-cell lymphoma (CTCL) — a type of blood cancer that mainly affects the skin — whose disease has come back or stopped responding to previous treatments. **You may be eligible if:** - You are 18 years or older - You have a confirmed diagnosis of CTCL at Stage Ib or higher - You have tried and failed or could not tolerate at least 2 prior treatments - You are in reasonably good health (ECOG score 0–2) - You have adequate organ function (blood, liver, kidneys) - You do not have HIV, or if you do, it is well controlled on antiviral therapy **You may NOT be eligible if:** - The lymphoma has spread to your brain or spinal cord - You are taking strong medications that interact with the study drug - You have significant heart disease or severely impaired lung function - You have an active serious infection - You have had another cancer in the past 5 years (with limited exceptions) - You have had a bone marrow or stem cell transplant - You have known active viral hepatitis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.